BioSpace News Archive

Biogen to receive license to co-develop and co-commercialize Denali’s small molecule LRRK2 inhibitor program, expanding pipeline of potential therapies in Parkinson’s disease and other movement disorders Biogen to receive exclusive option rights to two programs for neurodegenerative diseases utilizing Denali’s blood-brain barrier crossing TV technology platform, including for amyloid beta, plus right of first negotiation for two additional unnamed TV platform programs Denali to receive

Apex Physics Partners (APP), a leading medical physics business services support organization, is proud to announce a new partnership with Alyzen Medical Physics, a leader in therapy medical physics services.

In response to Hurricane Isaias, which has led the governors of South Carolina , North Carolina and Virginia to declare states of emergency, Blue Cross Blue Shield of Massachusetts (Blue Cross), Inc. is expediting access to care for affected members.

Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic medical device and technology company focused on unmet needs in oncology and viral diseases announced today that the National Institute for Dental and Craniofacial Rese

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced financial results for the second quarter ended June 30, 2020 and provided a corporate update.

Collaboration highlights the power and versatility of the proprietary Switch-Blocker technology, which may be applied to molecular diagnostics in COVID-19 and other infectious diseases, in addition to oncology applications currently commercialized and in development [06-August-2020] SAN DIEGO , Aug. 6, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading com

IDE submission to the FDA for C-Scan® planned for the end of 2020; Initiation of a U.S. pivotal study planned for 2021.

PTC Therapeutics, Inc. (NASDAQ: PTCT) is proud to announce that its Senior Vice President of Corporate and Patient Relations, Mary Frances Harmon, has been named to PharmaVOICE magazine’s annual list of the most inspiring people in the life sciences industry

GeneDx, Inc., a subsidiary of BioReference Laboratories, Inc., an OPKO Health company, announced the launch of GenomeXpress, a rapid genome sequencing test.

Submitted a New Drug Application to the U.S. Food and Drug Administration for the review of tenapanor as a first-in-class therapy to control serum phosphorus in adult patients with chronic kidney disease on dialysis Maintains strong balance sheet with $204.8 million in cash, cash equivalents and short-term investments